Physiomics Share News (PYC)
PYC Share
PYC Share
PYC Share
PYC Share
PYC
PYC Share
PYC Level 2
PYC Live
PYC Broker
PYC Directors
PYC Financial
PYC
PYC Short
PYC
Last checked at -
Thu, 28th Nov 2013 15:10
LONDON (Alliance News) - Shares in Physiomics PLC jumped 19% Thursday after it launched its drug combinations and regimens database DrugCard.
DrugCard collects publicly available pre-clinical and clinical drug regimen data into a searchable database.
Shares in the biotechnology company were trading up 19% at 0.190 pence Thursday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright © 2013 Alliance News Limited. All Rights Reserved.
TRADING UPDATES: CentralNic revenue doubles; Augean swing to profit
Read more
(Sharecast News) - Oncology consulting company Physiomics has entered into a new agreement with clinical-stage drug development company ValiRx, it announced on Monday, superseding the agreement between the two companies, which was announced in September 2011.
Read moreIN BRIEF: ValiRx Extends Collaboration Agreement With Physiomics
Read moreUK TRADING UPDATE SUMMARY: Focusrite Revenue Grows On Strong Demand
Read more(Sharecast News) - Oncology consultancy Physiomics announced on Thursday that its existing client, Merck, has committed to an initial tranche of projects for 2021 with a total value of £0.27m.
Read moreUK TRADING UPDATE SUMMARY: Airtel Investor To Sell 60 Million Shares
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read moreIN BRIEF: Physiomics Pens New Merck KGaA, Bicycle Therapeutics Deals
Read more(Sharecast News) - Oncology consultancy Physiomics has been awarded further contracts of an undisclosed value for projects with existing clients Bicycle Therapeutics and Merck.
Read moreIN BRIEF: Physiomics Annual Revenue Grows And Loss Narrows
Read moreUK TRADING UPDATE SUMMARY: Brickability Recovering Well From Pandemic
Read more(Sharecast News) - Oncology consultancy Physiomics announced on Friday that it has been awarded a contract by a new client, Japan-based global pharmaceutical company Astellas Pharma.
Read moreIN BRIEF: Physiomics Has No Explanation For Share Price Surge
Read morePhysiomics Raises New Funds To "Further Develop Its Business"
Read more(Sharecast News) - Oncology consultancy Physiomics has raised roughly £829,000 through a share issue to finance further development.
Read more
Last checked at